JI6 是一种有效、选择性且具有口服活性的 FLT3 抑制剂,对 FLT3-WT、FLT3-D835Y 和 FLT3-D835H 的 IC50 值分别约为 40、8 和 4 nM,同时还抑制 JAK3 和 c-Kit(IC50 值分别约为 250 和 500 nM),可用于急性髓性白血病的研究。
产品编号: MS-E55629 CAS No.: 856436-16-3 分子式: C19H17N3O4S 分子量: 383.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

JI6 是一种有效、选择性且具有口服活性的 FLT3 抑制剂,对 FLT3-WT、FLT3-D835Y 和 FLT3-D835H 的 IC50 值分别约为 40、8 和 4 nM,同时还抑制 JAK3 和 c-Kit(IC50 值分别约为 250 和 500 nM),可用于急性髓性白血病的研究。

生物实验数据

生物活性 JI6 is a potent, selective, and orally active FLT3 inhibitor with IC50 values of ~40, 8, and 4 nM against FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively, and it also inhibits JAK3 and c-Kit with IC50 values of ~250 and ~500 nM, respectively, making it useful for research on acute myeloid leukemia.
IC50 & Target FLT3 (WT):40 nM, c-Kit:~500 nM, FLT3 (D835H):4 nM, FLT3 (D835Y):8 nM, JAK3:~250 nM
体外研究
(In Vitro)

JI6 (3-1000 nM; 1-4 days) selectively inhibits the viability of MV4-11 cells in a dose-dependent manner, with an IC50 of ~25 nM.
JI6 (1-2000 nM; 48 h) potently inhibits the viability of HCD-57 cells expressing FLT3-ITD, FLT3-D835Y, and FLT3-D835H with IC50s of ~40 nM, but it displays essentially no effects on the parent HCD-57 or the cells transformed with JAK2V617F.
JI6 (100-500 nM; 24 h) induces apoptosis and cell cycle arrest in both FLT3-ITD- and FLT3-D835Y-expressing HCD-57 cells.
JI6 (50-500 nM; 3 h) inhibits phosphorylation of FLT3 and its downstream signaling transducers including ERK and Akt in FLT3-ITD- and FLT3-D835Y-transfromed HCD-57 cells.

Cell Viability Assay

Cell Line: MV4-11, HL60, Karpas 299, and Jurkat cells
Concentration: 3-1000 nM
Incubation Time: 48 hours
Result: Inhibited MV4-11 cells and no effects of JI6 on the three remaining cells at a concentration as high as 1 μM.

Apoptosis Analysis

Cell Line: FLT3-ITD- and FLT3-D835Y-transformed HCD-57 cells
Concentration: 100, 500 nM
Incubation Time: 24 hours
Result: Increased the percentage of apoptotic and necrotic cells and displayed no effects on the apoptosis of the parent HCD-57 cells.

Cell Cycle Analysis

Cell Line: FLT3-ITD- and FLT3-D835Y-transformed HCD-57 cells
Concentration: 100, 500 nM
Incubation Time: 24 hours
Result: Significantly reduced G2 and S phase cells and increased G1 phase cells in both FLT3-ITD and D835Y cells.

Cell Viability Assay

Cell Line: FLT3-ITD- and FLT3-D835Y-transformed HCD-57 cells
Concentration: 50, 100, 500 nM
Incubation Time: 3 hours
Result: Inhibited phosphorylation of FLT3, ERK1, ERK2 and Akt.
体内研究
(In Vivo)

JI6 (15 mg/kg; i.p. daily for 3 weeks) inhibits the proliferation of FLT3-D835Y-transformed HCD-57 in immunodeficient mice and prolongs the mice survival.
JI6 (25 mg/kg; p.o. daily for 3 weeks) suppresses myeloproliferative phenotypes in FLT3-ITD knock-in mice.
JI6 (100 mg/kg; a single i.p.) significantly inhibits phosphorylation of FLT3 and downstream signal transductionin mice expressing FLT3-D835Y.

Animal Model: NSG mice (10-12 weeks old, male) were implanted with FLT3-D835Y-transformed HCD-57 cells
Dosage: 15 mg/kg
Administration: I.p. daily for 3 weeks
Result: Reduced the spleen size and prolonged the survival of these mice.

化学信息

分子量 383.42
分子式 C19H17N3O4S
CAS No. 856436-16-3

储存&溶解度

溶解度信息
DMSO: 4.5 mg/mL (11.74 mM), Sonication is recommended.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础